Hormone Replacement Therapy

HRT: The Basics - Menopause Mission Control

• What is HRT? Pharmacological replacement of ovarian hormones (Estrogen ± Progestogen) as production wanes.
• Core Aims:
  • Relieve debilitating menopausal symptoms.
  • Prevent/manage long-term sequelae (e.g., osteoporosis).
• Primary Uses:
  • Vasomotor Symptoms (VMS): Hot flushes, night sweats.
  • Genitourinary Syndrome of Menopause (GSM): Vaginal atrophy, dyspareunia, recurrent UTIs.
  • Osteoporosis Prevention: Especially in premature ovarian insufficiency (POI) or high-risk women <60 years or within 10 years of menopause.

⭐ HRT remains the gold standard for alleviating moderate-to-severe menopausal vasomotor symptoms.

HRT: Types & Regimens - Elixir Ensemble

• Core Principle: Balance benefits & risks; individualize therapy duration and type.
• Types based on Uterus:
  • Estrogen Therapy (ET): For women without a uterus (post-hysterectomy).
    • Agents: Oral (CEE, estradiol), Transdermal (patch/gel; preferred for ↓VTE risk), Vaginal (for isolated urogenital symptoms).
  • Estrogen-Progestogen Therapy (EPT): For women with an intact uterus (progestogen prevents endometrial hyperplasia/cancer).
    • Progestogens: Micronized progesterone (often preferred, better CV profile), MPA, NETA, Dydrogesterone.
• EPT Regimens:
  • Continuous Combined: Daily Estrogen + Progestogen. Aim: amenorrhea after 6-12 months. (e.g., CEE 0.625mg + MPA 2.5mg).
  • Sequential (Cyclic): Daily Estrogen; Progestogen for 10-14 days/month. Result: predictable monthly withdrawal bleed.
  • Tibolone: Synthetic steroid; provides estrogenic, progestogenic, & weak androgenic effects.
  • TSEC (Tissue Selective Estrogen Complex): e.g., Conjugated Estrogens/Bazedoxifene. Alternative to EPT.

⭐ Transdermal estrogen bypasses first-pass hepatic metabolism, preferred with ↑VTE risk, hypertriglyceridemia, or liver issues.

HRT: Benefits vs. Risks - Balancing Act

• Benefits:
  • Vasomotor Symptoms (VMS): Gold standard for hot flashes, night sweats.
  • Urogenital Atrophy: Relieves vaginal dryness, dyspareunia, recurrent UTIs.
  • Osteoporosis: Prevents bone loss, ↓ fracture risk (hip, vertebral).
  • Mood & Sleep: May improve lability, insomnia.
  • Colorectal Cancer: Potential ↓ risk.
• Risks:
  • Breast Cancer: ↑ with combined Estrogen+Progestin (E+P) (duration-dependent); Estrogen-only (ET) in hysterectomized women shows less risk.
  • Endometrial Cancer: ↑ with unopposed ET (if uterus intact); Progestin is protective.
  • Venous Thromboembolism (VTE - DVT/PE): ↑ risk, especially with oral HRT, highest in 1st year.
  • Stroke: ↑ risk, particularly in older women or those with risk factors.
  • Coronary Heart Disease (CHD): Complex. "Timing Hypothesis" suggests initiation <60 yrs & <10 yrs postmenopause may be safer/beneficial.
  • Gallbladder Disease: ↑ risk.
• Balancing Act - Key Considerations:
  • Indication: Primarily for moderate-severe VMS.
  • Individualize: Based on age, time since menopause, personal risk factors (CVD, VTE, cancer history).
  • Dose & Duration: Use lowest effective dose for the shortest duration necessary.
  • Route: Transdermal route may offer lower VTE/stroke risk vs. oral.
  • Uterus Status: E+P if uterus intact; ET if hysterectomized.

⭐ The Women's Health Initiative (WHI) trial significantly impacted HRT prescribing, highlighting increased risks of breast cancer, CHD, stroke, and PE in certain populations, leading to more cautious use.

HRT: Contraindications & Monitoring - Safety Net Strategy

Contraindications (Absolute):

• Breast/Estrogen-dependent cancer
• Undiagnosed genital bleeding
• Active VTE/ATE (DVT, PE, MI, Stroke)
• Severe liver disease
• Pregnancy

• ⚠️ Key Safety: Add progestogen if uterus intact.
• Monitoring: BP, symptoms, annual mammogram. Endometrial check for unscheduled bleeding.

⭐ Unopposed estrogen in women with uterus significantly ↑ endometrial cancer risk.

High‑Yield Points - ⚡ Biggest Takeaways

• HRT is gold standard for vasomotor symptoms (VMS) & genitourinary syndrome of menopause (GSM).
• Unopposed estrogen if no uterus; add progestin if uterus present to prevent endometrial cancer.
• Major contraindications: History of breast/endometrial cancer, VTE, undiagnosed AUB, active liver disease.
• Principle: Lowest effective dose, shortest possible duration for symptom relief.
• Risks: ↑ VTE, ↑ stroke; combined (E+P) HRT slightly ↑ breast cancer risk.
• Key benefit beyond symptoms: Osteoporosis prevention in at-risk women_